Abstract Background Serotonin 2A receptor (5-HT2AR) agonists play a crucial role in multiple cognitive processes, namely executive functions, learning and memory. Owing partly to this, psychedelics such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline and ayahuasca might be valuable adjuvants in improving memory deficits and language impairment. Thanks to...
Central nervous system (CNS) injuries remain challenging to treat due to limited neurogenesis, inhibitory extracellular environments, and maladaptive neuroimmune responses. Psychedelic compounds, including classical serotonergic psychedelics, dissociative anesthetics, and empathogens, have re-emerged as mechanistically distinctive “psychoplastogens” capable of rapidly and persistently enhancing...
Brain oscillations represent frequency-specific neural phenomena essential for coordinating distributed brain activity and supporting cognition. The endocannabinoid system (ECS), particularly via cannabinoid receptor 1 (CB1R), plays a pivotal role in modulating neural oscillations through inhibitory circuit modulation, synaptic plasticity regulation, and long-range connectivity coordination....
Extant literature indicates mitochondrial dysfunction may contribute to the pathophysiology of depressive disorders. Preclinical data indicate that anesthetic doses of ketamine are associated with deficits in mitochondrial viability and function. Ketamine and esketamine have demonstrated rapid antidepressant effects in persons with difficult-to-treat depressive disorders. Herein, we aim to...
Opioid Use Disorder (OUD) continues to be a pressing public health crisis, marked by high relapse rates and limited treatment options. Ketamine, a non-competitive N-Methyl-D-Aspartate receptor (NMDAR) antagonist, has emerged as a promising therapeutic for numerous psychiatric illnesses due to its robust antidepressant properties and glutamate-mediated synaptic plasticity. However, ketamine's...
IntroductionOpioid use disorder (OUD) remains a major public health crisis despite evidence-based medications, including methadone, buprenorphine, and naltrexone. Persistent challenges with treatment retention, access, stigma, and incomplete response highlight the need for adjunctive pharmacotherapies targeting neurobiological systems beyond the mu-opioid receptor.MethodsWe conducted a...
Boosting brain plasticity could be useful in treating a number of conditions.Now researchers are looking at psilocybin and other psychedelic compounds -as well as exercise -to see how they can rewire the brain.
Psychopharmacology, once propelled by a series of serendipitous mid-20th-century discoveries, has matured into a field defined by mechanistic diversity, translational neuroscience, and an expanding array of circuit-based interventions. Despite more than 100 approved psychiatric drugs, remission rates for major depressive disorder and other serious mental disorders remain modest, underscoring...
Abstract Background Treatment-resistant depression (TRD) represents a major clinical challenge and is associated with substantial symptom burden, functional impairment, and poor prognosis. Beyond traditional monoaminergic models, converging evidence indicates that dysfunction of the glutamatergic system plays a central role in the pathophysiology of TRD, contributing to impaired neuroplasticity...
Abstract Background Lysergic acid diethylamide (LSD), a serotonergic psychedelic, has gained renewed interest for its potential anxiolytic effects in clinical trials. However, the neurobiological mechanisms underlying these effects remain poorly understood. Aims & Objectives The goal of this study is to understand the mechanism of action of LSD in animal models by using in vivo...